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HIV-1 Proviral DNA Loads (as Determined by Quantitative PCR) in
Patients Subjected to Structured Treatment Interruption after
Antiretroviral Therapy Failure
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Retrovirology Laboratory, Infectious Diseases Division, Federal University of São Paulo (UNIFESP), São Paulo, Brazil,a and Laboratório Centro de Genomas,b Fundação Pró-
Sangue Hemocentro de São Paulo, Departamento de Biologia Molecular,c and Discipline of Information Technology, School of Medicine,d University of São Paulo (USP),
São Paulo, Brazil
The impact of Structured Treatment Interruption (STI) in peripheral bloodmononuclear cell (PBMC) proviral reservoirs in 41
highly active antiretroviral therapy (HAART)-treated viremic individuals at baseline and 12 weeks after STI was determined us-
ing quantitative PCR (qPCR). Viral load increased 0.7 log10 and CD4 decreased 97.5 cells/mm
3 after 12 weeks. A total of 28 of the
41 individuals showed an increased proviral load, 19 with a statistically significant increase above 10%. An increase in active viral
replication is an important factor in the replenishment of the proviral reservoir even for short time periods.
The persistent presence of proviral DNA associated with thegeneration of replication-competent viruses in various cellular
compartments has been a major barrier to virologic control of the
infection (1, 2). Latent viral reservoirs are established very early
during primary infection, and latently infected CD4 T lympho-
cytes can serve as a long-term stable reservoir for the virus, with a
nearly 44-year half-life (3–5, 8). Structured Treatment Interrup-
tion (STI) among individuals harboring replicating resistant HIV
strains leads to reemergence of wild-type viruses, with a conse-
quent increase in viral load (VL) (5, 7). We developed a quantita-
tive PCR (qPCR) assay targeting proviral HIV-1 DNA and at-
tempted to determine the impact of STI in the proviral reservoir. A
total of 41 samples from patients failing highly active antiretrovi-
ral therapy (HAART) were subjected to a 12-week STI. Patients
were sampled between 1999 and 2000 at baseline (before STI) and
after 12 weeks of STI. Informed written consent was approved by
the Institutional Review Board of the Federal University of São
Paulo (UNIFESP; 0189/05). Genomic DNA was extracted from
peripheral blood mononuclear cells (PBMCs) (QIAamp blood kit;
Qiagen, Valencia, CA). VL was measured using a Cobas Amplicor
HIV-1 Monitor, version 1.5 (Roche Molecular Systems, Inc.,
Branchburg, NJ), and CD4 levels were determined using a Becton,
Dickinson FACScan Flow Cytometer (Foster City, CA). The qPCR
primers and probe amplified a 202-bp fragment of the integrase
gene (bp 4309 to 4511 in HXB2). The albumin gene was amplified
according to the method of Désiré et al. (6). The standard curve
was generated by a 10-fold serial dilution from 1 108 copies of
plasmid DNA down to one starting molecule. Amplification was
performed using an iCycler (Bio-Rad Laboratories, Hercules,
CA). For relative quantifications, the normalized value of the
HIV-1 proviral load (HIV PL) was calculated as [HIV copy num-
ber/(albumin copy number  2  20)]. The values of HIV-1 PL
are expressed as HIV copy number/albumin genomic equivalents.
We used a plasmid as a positive control at a concentration of 1,000
copies/ml (in duplicate). The intra-assay reproducibility was cal-
culated by testing the recombinant plasmid dilutions at from 107
to 102 copies/ml seven times in the same experiment. To estimate
the interassay reproducibility, the later dilutions were analyzed
independently on different days by different technicians. We ini-
tially aimed to validate the qPCR before application to clinical
samples. As shown in Fig. 1, amplification of the recombinant
plasmid at various concentrations showed linearity of 8 orders of
magnitude. The slope of the standard curve was3.6 (R2 0.99),
and PCR efficiency was 88.9%. For specificity analysis, HIV PL in
culture supernatants was determined for subtypes B (5 log10/albu-
min), F (4 log10/albumin), and C (5 log10/albumin). The repro-
ducibility was determined by calculating percent coefficient of
variation (CV) from 10 copies and 107 (1.63% and 3.74%, respec-
tively). CVs for interassay determinations were 3.29% and 6.07%
(107 and 102, respectively). Standard curve analysis for albumin
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FIG 1 HIV real-time PCR plasmid integrase standard curve, showing linearity
over a range of 8 orders of magnitude. The least-squares regression was calcu-
lated from plots of values measured for cycle threshold (Ct) (y axis) versus
input plasmid DNA over a range of 101 to 108/ml (x axis) tested in duplicate
PCR wells per dilution. The correlation coefficient was 0.99, and the slope of
the line was3.6.
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revealed 88% amplification efficiency (R2 0.98; slope3.62;
intercept 41).
All individuals presented genotypic resistance to all three anti-
retroviral classes at baseline, followed by the reemergence of wild-
type virus at week 12 (data not shown). Of the 41 study patients,
83% were males; the median age was 46 years (range, 39 to 53),
and the median HIV-1 PL was 0.61 log10. The averages of HIV-1
PL at baseline and week 12 were 0.61 log10 and 0.63 log10, respec-
tively (t test 1.64; P 0.11). At 12 weeks, the average plasma VL
was significantly higher than the baseline (t test 6.08; P 0.01).
Fifty percent of patients showed a decrease of 50% or higher in
CD4 T cell counts after 12 weeks of STI (Table 1). Comparisons
showed that individual rates of change of HIV-1 PL at week 12
tended to increase in 28 patients (70%), among whom19 (47.5%)
showed an increase higher than 10%. For those 19 patients, the
median HIV-1 PL was 0.68 log10/albumin genomic equivalents (t
test  6.74; P  0.01). Fifteen patients (37.5%) showed an in-
crease in VL of1 log10 after 12 weeks, and 10 of those (75%) also
showed an increase higher than 10% in the HIV-1 PL at week 12.
Conversely, among the 19 patients who showed a VL increase
higher than 10% at week 12, 10 had an increase in VL of1 log10,
whereas 5 of 21 patients (23.8%) who presented with an increase
in HIV-1 PL below 10% had an increase in VL of1 log10 (Fisher’s
exact test; P 0.06). There was no correlation between HIV-1 PL
and CD4 counts. HIV-1 PL quantitation is potentially a useful
research tool for (i) understanding HIV-1 dynamics and compart-
mentalization, (ii) refining the monitoring of antiretroviral treat-
ment, or (iii) use in studies aiming at HIV-1 eradication. We
therefore developed two systems for absolute quantification that
target the HIV-1 integrase gene and the human albumin gene. We
developed a methodology that enables us to retrospectively ana-
lyze either stored samples that lack previous cell quantification or
samples of nonviable cells accurately quantifying distinct HIV
clades. We attempted to analyze variations in the HIV-1 PL in
samples collected from viremic individuals before and after 12
weeks of STI. Interestingly, 28 of 41 individuals tended toward an
increase in the HIV-1 PL after 12 weeks. Of these, 19 had a statis-
tically significant increase of HIV-1 PL greater than 10%, which
was accompanied by a notable increase in plasma VL. This sug-
gests that, even for short time periods, active viral replication is an
important factor in the replenishment of the proviral reservoir.
Almost all individuals showed an important drop in CD4 T cell
counts after STI; nevertheless, the relative numbers of infected
cells did tend to increase. STI among individuals failing HAART
leads to the reemergence of wild-type HIV, an increase in VLs, and
a decrease of CD4 T cell counts, and it can be a limiting factor in
the increase of CD4 counts after antiretroviral treatment is re-
sumed (9, 10). In addition, we think it is highly significant that
there is an increase in the pool of HIV-1-infected cells after STI,
even among previously viremic individuals. Additional studies
quantifying HIV provirus in both different compartments and
different cell subpopulations vis-a`-vis antiretroviral exposure or
interruption, or in the presence of HIV strains with different rep-
licative capacities, may be fundamental for fine-tuning the under-
standing of HIV dynamics among infected individuals.
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TABLE 1 Characteristics of STI patients
Patient characteristic
Median (range) resulta
Baseline Wk 12
CD4 count (cells/mm3) 218 (10–760) 97.5 (1–550)
Plasma HIV RNA (log10 copies/ml) 4.90 (1.72–6.23) 5.60 (4.2–6.89)
HIV DNA (log10 copies/genomic
equivalent)
0.61 (0.23–0.92) 0.62 (0.53–1.04)
a Statistical analyses were performed using Minitab software, version 15.
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